Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMAcTION: AAA817 versus standard of care in PSMA-positive metastatic castration-resistant prostate cancer progressing during or after [177Lu]Lu-PSMA therapy
CTR20250912Phase 3Active
- Sponsor
- Novartis
- Start
- May 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Ac-225-PSMA in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Novartis. Started May 2025; status: active.
02
Drugs
Ac-225-PSMA
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20250912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250912.